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ABSTRACT: With the advance of high-throughput sequencing technologies, it has become feasible to investigate the influence
of the entire spectrum of sequencing variations on complex human diseases. Although association studies utilizing the new
sequencing technologies hold great promise to unravel novel genetic variants, especially rare genetic variants that contribute
to human diseases, the statistical analysis of high-dimensional sequencing data remains a challenge. Advanced analytical
methods are in great need to facilitate high-dimensional sequencing data analyses. In this article, we propose a generalized
genetic random field (GGRF) method for association analyses of sequencing data. Like other similarity-based methods (e.g.,
SIMreg and SKAT), the new method has the advantages of avoiding the need to specify thresholds for rare variants and
allowing for testing multiple variants acting in different directions and magnitude of effects. The method is built on the
generalized estimating equation framework and thus accommodates a variety of disease phenotypes (e.g., quantitative and
binary phenotypes). Moreover, it has a nice asymptotic property, and can be applied to small-scale sequencing data without
need for small-sample adjustment. Through simulations, we demonstrate that the proposed GGRF attains an improved or
comparable power over a commonly used method, SKAT, under various disease scenarios, especially when rare variants play
a significant role in disease etiology. We further illustrate GGRF with an application to a real dataset from the Dallas Heart
Study. By using GGRF, we were able to detect the association of two candidate genes, ANGPTL3 and ANGPTL4, with
serum triglyceride.
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Introduction
Genome-wide association studies (GWAS) have been com-
monly used to evaluate the association of millions of sin-
gle nucleotide polymorphisms (SNPs) with complex human
diseases. To date, more than 1,000 diseases-related genetic
variants have been revealed by GWAS [Hindorff et al., 2009].
Despite such successes, for most complex diseases the identi-
fied genetic variants only account for a small percentage of the
disease heritability [Manolio et al., 2009]. One possible ex-
planation is that GWAS are based on the “CommonDisease–
Common Variant” hypothesis. Under this hypothesis, com-
plex diseases are likely caused by multiple common variants
with appreciable frequencies (e.g., >1%), each conferring a
small or moderate effect [Schork et al., 2009]. However, evi-
dence from previous studies (e.g., genetic studies of inherited
hearing loss and lipid metabolism) suggests that the genetic
etiology of complex diseases can be highly heterogeneous
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[McClellan and King, 2010], and rare variants within a gene
or across different genesmay collectively have a significant in-
fluence on diseases [Bodmer and Bonilla, 2008; Schork et al.,
2009]. The fast development of next generation sequencing
technologies facilitates the detection of millions of rare se-
quence variations [Ansorge, 2009; Bodmer andBonilla, 2008;
Schuster, 2008], and enables us to comprehensively assess the
potential contribution of rare variants in complex diseases
[Eichler et al., 2010]. Meanwhile, the emergence of a large
amount of sequence variation also poses a great challenge for
the statistical analyses of high-dimensional sequencing data.
Advanced statistical methods are in great need to evaluate the
role of rare variants, in conjunction with common variants,
in complex human diseases.
Standard statistical methods generally have low power for
testing individual rare variants because of the low allele fre-
quencies of rare variants. Therefore, a number of methods
were proposed to collapse multiple rare variants in a gene,
or a genetic region, into one group. Among these methods,
the combined multivariate and collapsing method collapses
rare variants by evaluating whether any rare allele occurs at
any loci for a subject [Li and Leal, 2008]; Morris and Zeggini
C© 2014 WILEY PERIODICALS, INC.
[2010] suggested collapsing the rare variants by counting the
rare alleles across all loci; the weighted sum test calculates
a weighted average of rare alleles [Madsen and Browning,
2009], where the weights are based on the minor allele fre-
quencyof each rare variant;HanandPanused adata-adaptive
sum test to account for the possible bidirection of genetic
effects [Han and Pan, 2010]. These methods, commonly re-
ferred to as burden tests, can improve power by combing
multiple rare variants into a “super” variant, and thus reduce
the burden of multiple testing. A major disadvantage of bur-
den tests is that aminor allele frequency threshold (e.g., <1%)
needs tobe specified to collapse the variants,which is often ar-
bitrary. Several methods with a data-adaptive threshold were
also proposed [Price et al., 2010; Zawistowski et al., 2010].
Nevertheless, these methods usually require a permutation
test, which can be computationally intensive.
Unlike burden tests, which form statistics on the collapsed
rare variants, similarity-based methods build the statistics by
linking the genetic similarity of individuals to their pheno-
typic similarity. Wessel and Schork discussed a number of
choices to calculate genetic similarity, and proposed a multi-
variate distance matrix regression by using the genetic simi-
laritymatrix as response variables [Wessel and Schork, 2006].
Tzeng et al. measured haplotype similarity by the average
allelic sharing across variants, and evaluated the gene-trait
association by testing the regression coefficient of haplotype
similarity on trait-similarity [Tzeng et al., 2009]. This pro-
posed method, referred to as SIMreg, was later adapted as
a random-effect model to study gene–environment interac-
tions [Tzeng et al., 2011]. More recently, kernel machine-
based methods, such as the sequence kernel association test
(SKAT) [Lee et al., 2012; Wu et al., 2010, 2011], have gained
popularity. SKAT aggregates the genetic association through
a kernel matrix, which is flexible for testing a large number
of variants while adjusting for covariates. These similarity-
based methods generally avoid selection of thresholds, allow
for multiple variants with different directions and magni-
tudes of effects, and are computationally efficient without
requiring a permutation test.
The similarity-based methods build on the concept that, if
there is a gene-phenotype association, the genetic similarity
between two individuals will lead to their phenotypic sim-
ilarity. A similar concept has been used in imaging analysis
and spatial analysis, in which subjects who are close to each
other on amapor in space tend to have similar outcomes. The
outcomes of all subjects, each corresponding to a location in
a space, form a stochastic process, referred to as a random
field with random coordinate variables that are spatially cor-
related in certainways [Besag, 1974]. The analogywith spatial
statistics motivates the use of a random field to genetic re-
search. A genetic random field model was recently proposed
for quantitative phenotypes [He et al., 2013]. In this arti-
cle, we propose a generalized genetic random field (GGRF)
method for the statistical analysis of sequencing data. In this
method, we view phenotypes of individuals as a randomfield
in a Euclidean space spanned by their sequenced genotypes.
Each individual has a location in this space determined by
his/her genotypes. In the presence of an association, individ-
uals tend to have similar phenotypes if they are “adjacent”
in the Euclidean space. The proposed method can be applied
to phenotypes with a variety of distributions (e.g., quantita-
tive and binary phenotypes), through a GEE framework. It
can also integrate into the analysis of both common and rare
variants, and evaluate their combined contribution to disease
phenotypes. Similar to the existing similarity-basedmethods
(e.g., SIMreg and SKAT), GGRF has a number of advantages.
It avoids selection of thresholds, allows for multiple variants
with different directions and magnitude of effects, and is
computationally efficient for high-dimensional sequencing
data analysis. Furthermore, it has a nice asymptotic property,
and can be applied to small-scale sequencing data without
need of small-sample adjustment. We compare the perfor-
mance of GGRF with that of SKAT via simulation studies.
The proposed method is further illustrated with an appli-
cation to a sequencing dataset from the Dallas Heart Study
(DHS).
Materials and Methods
Generalized Genetic Random Field
The GGRF method is motivated by the general idea that,
if the genetic variants are jointly associated with the phe-
notypes, the genetic similarity between subjects contributes
to their phenotypic similarity. In GGRF, we map individuals
into a Euclidean space, where each individual has a loca-
tion determined by his/her sequenced genotype. If there is a
genotype–phenotype association, we expect individuals who
are adjacent in the Euclidean space havemore similar pheno-
types than those that are further apart. Based on this concept,
we model the conditional phenotypic mean of each individ-
ual as a linear function of a weighted sum of phenotypes of
the remaining individuals, where the weights are determined
by the genetic similarity of the individuals [He et al., 2013].
Assume K variants in a gene or a genetic region were se-
quenced and M covariates (e.g., age) were measured for N
subjects. Let yi be the phenotypic value for the i-th subject,
Gi = (g i,1, g i,2, . . . . . . , g i,K )′ be the genotypes of K sequence
variants, and X i = (xi,1, xi,2, . . . , xi,M)′ be the covariates. We
can express a phenotypic mean for each individual as a linear
function of covariates and a weighted sum of the phenotypes
of all other individuals,
E (yi | y–i) = μi + γ
∑
j =i
s i,j (yj – μj ), (1)
where y–i denotes phenotypes for all subjects other than sub-
ject i and μi = f (X ′iβ), where f(·) is the mean function as in
a generalized linear model, used for controlling covariates.
Specifically, if the phenotype is quantitative, we use the iden-
tity link f (x) = x; if the phenotype is binary,weuse the logistic
link f (x) = exp(x)1+exp(x) . si,j is a weight representing the relative
contribution of the j-th subject in predicting the phenotype
of subject i, which is determined by the genetic similarity
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between subjects i and j . γ is a nonnegative coefficient mea-
suring the ability of all the remaining subjects to predict the
phenotype of subject i, which can also be interpreted as the
magnitude of the joint association of K sequence variants
with the phenotype. If none of the sequence variants are as-
sociated with the phenotype (i.e., γ = 0), the phenotype of
subject i will be independent of the phenotypes of others, re-
gardless of their genetic similarity. On the other hand, a large
γ indicates a strong genetic contribution to the phenotype.
Therefore, to examine the joint association of K sequence
variants with the phenotype, we test a null hypothesis with a
single parameter, H0 : γ = 0.
Statistical Inference
In this section, we propose a generalized estimating equa-
tion (GEE)-based statistic to test the null hypothesis,H0 : γ =
0. For convenience, we rewrite equation (1) in matrix form,
E (Y |Y–) = f (Xβ)+γS[Y – f (Xβ)], (2)
whereY = (y1, y2, . . . , yN)′, X = (X 1,X 2, . . . ,XN)′ and Y– =
(y–1, y–2, . . . , y–N)′. μ = f (Xβ), where μ = (μ1, . . . , μN)′
represents the nongenetic mean. S is an N × N similar-
ity matrix with si,j as its element in row i and column j,
1 ≤ i = j ≤ N, and zeros on the diagonal. The parameters
in equation (2) can be estimated by solving the following
unbiased estimating equation:
Uγ(β, γ) =
[
∂E (Y |Y–)
∂γ
]′
[Y – E (Y |Y–)]
= (Y – μ)′S(I – γS)(Y – μ) = 0. (3)
Based on equation (3), we estimate γ,
γˆ =
(Y – μˆ)′S(Y – μˆ)
(Y – μˆ)S2(Y – μˆ)
,
where the nongenetic mean, μˆ, can be estimated under the
null hypothesis γ = 0. We defineW as a diagonal matrix with
its i-th element wi = 1 for quantitative phenotypes, and wi =
μˆi(1 – μˆi) for binary phenotypes with a logistic link. Large
values of γ suggest an association of the sequence variants
with the phenotype. Given the observed value γˆ, γˆobs , the
P-value of the association test can be calculated by
PH0 (γˆ > γˆobs) = P ((Y – μˆ)
′(S – γˆobsS2)(Y – μˆ) > 0).
We note that (Y – μˆ)′(S – γˆobsS2)(Y – μˆ) asymptotically fol-
lows a mixture of Chi-squares,
∑K
k=1 λkχ
2
1,k, where (λ1,
. . . , λK ) are the eigenvalues of the matrix P 1/2(S –
γˆobsS2)P 1/2 and P = W – WX (X ′WX )–1X ′W [Wu et al.,
2011]. Given the asymptotic distribution, Davies’ method
can then be used to obtain the significance level of the asso-
ciation test [Davies, 1980].
The test statistic used in GGRF holds a nice asymptotic
property for small sample size studies. For quantitative phe-
notypes, the test statistic γˆ is ancillary to the variance of Yi
because the variance term in the numerator anddenominator
are cancelled out. Without using any asymptotic approxima-
tion, the test is an exact test and is therefore not conservative.
For binary phenotypes, the estimated variance of Y depends
on estimated means. When there is no covariate or covari-
ates only have small or moderate effect on the mean, the test
statistic is still not conservative because the estimated vari-
ance in the numerator and denominator are also cancelled
out or nearly cancelled out. The asymptotic approximation
is only needed when the covariates have large impact on the
mean.
Weight and Similarity Functions
Sequencing data comprise a large number of common and
rare variants. Although rare variants have low allele frequen-
cies, they could contribute significantly to the phenotype.
A good choice of weights and similarity metrics that reflect
the contribution of rare variants and the underlying genetic
similarity between individuals can improve the power of the
association test. In this paper, we consider four commonly
used weights. As we discuss later, each set of weights assumes
different contributions of rare variants to the disease. Given
the prespecified vector of weights, ω = (ω1, ω2, . . . , ωK )′ for
K sequence variants, we propose a general p-norm distance-
based genetic similarity (NDS) between subject i and subject
j as:
si,j = B – ‖Gi – Gj ‖p = 2
(
K∑
k=1
ωk
)1/p
–
(
K∑
k=1
ωk|g i,k – g j ,k|p
)1/p
, (4)
where ‖Gi – Gj ‖p is the p-norm distance between subjects i
and j based on their genotypes, and B is the corresponding
mathematical supremum over the distance between any two
subjects. Note that the 1st order NDS (p = 1) is equivalent
to the commonly used identity-by-state (IBS) metric, and
the 2nd order NDS (p = 2) is based on the commonly used
Euclidean distance.
Results
Simulation Studies
We conducted simulation studies to compare the perfor-
mance of GGRFwith a commonly usedmethod, SKAT. In the
simulations, we varied the underlying disease model, choice
of weights, causal variants/noise variants ratios, and simi-
larity metrics. In each case, we compared power and type I
error of the two methods. To mimic a real data scenario, the
genotype data used in the simulations was based on the ex-
ome sequencing data of 697 subjects from the 1000 Genome
project [Almasy et al., 2011]. The genotype data comprised
508 sequence variants located on chromosome 22 with mi-
nor allele frequencies (MAFs) ranging from 0.07% to 49.4%.
The distribution of the MAFs was given in Figure 1. The
majority of the 508 sequence variants were rare variants with
MAFs less than 1%. The phenotypic values of the samples
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Figure 1. Distribution of theminor allele frequencies of 508 sequence
variants on chromosome 22 in exome sequencing data from the 1,000
Genome Project.
were simulated based on the genotypes and assumed disease
models that were discussed in detail below. In each simula-
tion, type I error and power of the two methods were esti-
mated based on 1,000 replicates. For comparison purposes,
IBSwas used as the similaritymetric forGGRF and SKAT, un-
less specified otherwise. In the simulation studies described
below, we focused on the comparison of GGRF and SKAT for
one-direction of effect sizes. The performance of SKAT and
other commonly used Burden tests were extensively com-
pared in previous studies [Lee et al., 2012; Wu et al., 2011].
In the Appendix, we also showed Burden test tended to have
the highest power under one-direction of effect sizes, but the
proposed GGRF with an appropriate kernel was able to share
similar advantages with SKAT over Burden test, for being ro-
bust to bidirection of effect sizes (See Fig. B1 in Appendix).
Such results were consistent with previous studies and were
not detailed here.
Simulations I: Various Prespecified Weights under Various
Disease Models
BothGGRFandSKATcanuseprespecifiedweights toboost
the power of association tests, and their performance may
depend on how well the weights reflect the relative contribu-
tion of the genetic variants to the disease. Without any prior
knowledge of the underlying disease model, the weights are
often prespecified as a function of MAFs. In this simulation,
we chose four weight functions and evaluated their influence
on the methods’ performance.
1. Unweighted (UW):
ωj = 1, 1 ≤ j ≤ 508.
Figure 2. Shape of four types of weight functions used in the simula-
tions. Maximum weight at MAF of 0.07% was rescaled to be 1 for each
weight function. The scaling does not change the relative contribution
of variants.
2. Beta distribution type of weights (BETA):
ωj = dbeta(MAFj , 1, 25)
2 1 ≤ j ≤ 508,
where the weight follows a beta distribution with shape
parameters 1 and 25.
3. Weighted sum statistics type of weights (WSS):
ωj =
1
MAFj (1 – MAFj )
1 ≤ j ≤ 508.
4. Logarithm of MAFs as weights (LOG):
ωj = – log10(MAFj ) 1 ≤ j ≤ 508.
The four weight functions can be visualized in Figure 2.
From Figure 2, UW gives equal consideration to all the se-
quence variants, while the other weight functions (i.e., BETA,
WSS, and LOG) give higher priority to low-frequency se-
quence variants. Among the latter three weight functions,
LOG gives the most consideration to common variants with
MAF greater than 5%; WSS gives nearly zero weight to vari-
ants with MAF greater than 1%; BETA gives slightly more
weight than LOG for MAF less than about 1.5%, thereafter
decreases much faster than LOG, and approaches zero for
variants withMAF greater than 10%. These weight functions
give distinct consideration to the sequence variants. It is ap-
parent that the statistical power on adopting various weight
functionswouldbe affectedby theunderlyingdiseasemodels.
To compare the power of twomethods, we randomly selected
fifty sequence variants as causal variants, and simulated their
phenotypes according to the following models:
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a. For quantitative phenotypes:
yi = μ +
50∑
k=1
βj k g i,j k + εi ;
where εi ∼ N(0, 1).
b. For binary phenotypes:
logit(p (yi = 1)) = μ +
50∑
k=1
βj k g i,j k ,
where g i,j k denotes the genotype of the k-th causal variant
for subject i and was coded as additive (i.e., g i,j k = 0 for
AA, g i,j k = 1 for Aa, and g i,j k = 2 for aa). βj k was used to
measure the effect of the k-th causal variants, 1 ≤ k ≤ 50.
For quantitative phenotypes, the intercept μ was set to be
0. For binary phenotypes, μ was adjusted to ensure that
the case/control ratio was approximately 1:2.
In our simulations, we considered four disease models by
varying the effect sizes, βj k . Each disease model was included
to favor one of the weight functions.
S1. The effect sizes of all causal variants were equal:
βj k = βS1 , for 1 ≤ k ≤ 50; and
βj = 0, if j /∈ {j1, j2, . . . , j50}.
S2. The effect sizes of causal variants were proportional to the
BETA weights described above:
βj k = βS2 × dbeta(MAFj k , 1, 25)2, for 1 ≤ k ≤ 50; and
βj = 0, if j /∈ {j1, j2, . . . , j50}.
S3. The effect sizes of causal variants were proportional to the
WSS weights described above:
βj k =
βS3
MAFj k(1 – MAFj k)
, for 1 ≤ k ≤ 50; and
βj = 0, if j /∈ {j1, j2, . . . , j50}.
S4. The effect sizes of causal variants were proportional to the
LOG weights described above:
βj k = βS4 log10(MAFj k), for 1 ≤ k ≤ 50; and
βj = 0, if j /∈ {j1, j2, . . . , j50}.
In S1–S4, the parameters βS1 . . . βS4 were adjusted to en-
sure the power of the two methods were within a reasonable
range. In S1, because all causal variants had equal effect size,
common variants with higher MAFs were expected to con-
tribute more to the phenotypes than rare variants. On the
other hand, rare variants played more important roles than
common variants in S2–S4 due to their relatively larger effect
sizes.
To evaluate type I error, the phenotypes were simulated in-
dependently of the genetic variants. The quantitative pheno-
types were simulated as, yi = εi , while the binary phenotypes
were simulated as p (yi = 1) = 1/3. Both GGRF and SKAT
were then applied to 1,000 replicates of the simulated data to
evaluate type I error.
Simulation II: Varying Causal Variants/Noise Variants Ratios
In practice, the investigator usually does not know how
many sequence variants are associated with the phenotypes.
Both GGRF and SKAT are able to handle multiple sequence
variants. However, including noise variants may affect the
performance of bothmethods. In simulation II, we evaluated
the performance of the two methods by gradually increasing
the number of noise variants in the analysis. Similar to sim-
ulation I, four disease scenarios (i.e., S1–S4) were simulated
by randomly selecting 50 variants as the causal variants. For
each disease scenario, we started with the analysis without
any noise variants, and then gradually increased the number
of noise variants to 50, 150, 250, 350, and 458. The corre-
sponding casual/noise variants ratios are approximately 1:0,
1:1, 1:3, 1:5, 1:7, and 1:9. For bothmethods, the BETAweights
(i.e., the default option of SKAT) were used to evaluate power
and type I error.
Simulation III: Various Similarity Metrics
Both GGRF and SKAT can use a wide variety of similarity
metrics to enhance their performance. In simulation III, we
evaluated the performance ofGGRFandSKATwith the use of
different similaritymetrics. ForGGRF, we proposed a general
p-norm distance-based similarity metric, and evaluated up
to order of 4 (i.e., P = 4), denoted as D1S, D2S, D3S, andD4S,
in the simulation. For SKAT, the IBS- and linear-kernels were
evaluated. Note that the 1st order NDS (D1S) had the same
form as the IBS-kernel. In each simulation, the phenotypes
were simulated according to the diseasemodel S4 as described
above. While applying both methods, the BETA weights (i.e.,
the default option of SKAT) were used.
Simulation Results
Simulations I: Various Prespecified Weights Under Various
Disease Models
The simulation results for both quantitative and binary
phenotypes were summarized in Figure 3. For all prespec-
ified weights (i.e., UW, BETA, WSS, and LOG), the type I
error of GGRF was well controlled at the 5% level. On the
other hand, when the prespecified weights were not UW,
SKAT showed conservative type I error (i.e., considerably less
than 5%), especially when the weight function was chosen in
favor of rare variants (e.g., WSS). We also found that when
WSS was used, the type I error of SKAT could be even more
conservative under binary phenotypes.
In terms of statistical power, both methods attained high-
est power when the chosen weights reflected the underlying
disease scenarios (i.e., UW for S1, BETA for S2, WSS for S3,
and LOG for S4). SKAT attained higher power than GGRF
in disease scenario S1, while GGRF attained higher power
than SKAT in all the other disease scenarios (i.e., S2, S3,
and S4), across all weights. This indicated that SKAT out-
performed GGRF when common variants contributed more
to the disease than rare variants, while GGRF outperformed
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Figure 3. Type I error andPower of GGRF andSKATon using four SNP-specificweights under four diseasemodels. Left: Quantitative Phenotypes,
Right: Binary Phenotypes; T1E: Type I Error; S1–S4: power under various disease scenarios. S1: effect sizes of causal variants are all equal; S2:
effect sizes of causal variants are proportional to BETA weights; S3: effect sizes of causal variants are proportional to WSS weights; S4: effect
sizes of causal variants are proportional to LOG weights.
SKAT when the rare variants played more important roles
than common variants.
Simulation II: Varying Causal Variants/Noise Variants Ratios
The simulation results for various causal variants/noise
variants ratios were summarized in Figure 4. The results were
similar for quantitative and binary phenotypes. In all simula-
tions, the type I error of GGRFwas well controlled. Similar to
Simulation I, SKAT showed conservative type I error, which
was consistently less than 5%. We also found the type I error
of SKAT was close to 5% if no noise loci were included.
The power of both methods decreased when the num-
ber of noise variants increased. For disease scenarios S2–
S4, the power of GGRF was consistently higher than that of
SKAT. This result concurred with Simulation I, indicating
that GGRF outperformed SKAT when the rare variants had
a major contribution to the phenotype. In addition, when
common variants had more influence on the disease pheno-
type than rare variants (i.e., S1) and the majority of variants
were causal, GGRF could still have a better performance than
SKAT. However, as the number of noise variants increased,
the power of SKAT decreased more slowly than GGRF.
When a large number of noise variants were included, SKAT
would attain higher power thanGGRFunder disease scenario
S1.
Simulation III: Various Similarity Metrics
The simulation results for various similarity metrics were
summarized in Figure 5. From simulations I and II, we ob-
served the conservative type I error of SKAT. In a recent exten-
sion of SKAT, a bootstrap approach was proposed to address
the issue of conservative type I error [Lee et al., 2012]. In this
simulation, we also evaluated the performance of SKAT after
bootstrap adjustment. Note that bootstrap adjustment was
only available for SKATwith thebinaryphenotype, the linear-
kernel, and the BETA weight. A large number of bootstrap
samples would also significantly increase the computational
effort.
Similar to Simulations I and II, GGRF had well-controlled
type I error (∼5%) for all similarity metrics (i.e., IBS, D2S,
D3S, and D4S). On the other hand, SKAT had conservative
type I errors for both IBS- and linear-kernels. However, af-
ter the bootstrap adjustment, the type I error of SKAT was
corrected to ∼5%.
AlthoughGGRF canuse any order ofNDS, its performance
depends on how well the chosen NDS reflects the underlying
genetic similarity. When the order increases, the model tends
to put higher weights on the remote individuals (i.e., individ-
uals who are genetically less similar). The model reaches its
optimal performance when the estimated genetic similarity
(i.e., weights) approaches the underlying genetic similarity.
In our simulation that assumed an additive model, GGRF
attained the highest power when D2S was used. The power
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Figure 4. Type I error and Power of GGRF and SKATwith decreasing ratio of casual variants/noise variants. Left: Quantitative Phenotypes, Right:
Binary Phenotypes; T1E: Type I Error; S1–S4: power under various disease scenarios. S1: effect sizes of causal variants are all equal; S2: effect
sizes of causal variants are proportional to BETA weights; S3: effect sizes of causal variants are proportional to WSS weights; S4: effect sizes of
causal variants are proportional to LOG weights.
of GGRFwas comparable on using either IBS or D2S, both of
which attained substantially higher power than D3S or D4S.
Therefore, a low order of NDS, such as IBS or D2S, is pre-
ferred for the practical use when the mode of inheritance is
additive. On the other hand, without bootstrap adjustment
the power of SKAT was comparable on using either the IBS-
or linear-kernel. The bootstrap adjustment of SKAT with the
linear-kernel would also increase its statistical power.
It should be noted that the similarity metrics used for
GGRFand thekernel functionof SKATare fundamentallydif-
ferent. The similaritymetrics for GGRF are based on distance
metrics. The linear-kernel is not a distance-basedmetric, and
should not be used forGGRF. A comparison of the twometh-
ods using various similarity metrics/kernel functions is not
straightforward. Both D2S of GGRF and the linear-kernel of
SKAT can be calculated efficiently, and thus are suitable for
analyzing large-scale datasets. Our simulation demonstrated
that without bootstrap adjustment D2S of GGRF performed
better than the linear-kernel of SKAT. After bootstrap adjust-
ment, SKAT attained a power comparable to that of GGRF,
but with an increased computational requirement.
Application to the DHS
We applied both GGRF and SKAT to a sequencing dataset
from the DHS [Romeo et al., 2009]. The dataset com-
prised2,658 individuals and four candidate genes,ANGPTL3,
ANGPTL4, ANGPTL5, and ANGPTL6. The four genes are
members of the ANGPTL family that has been previously
suggested to play a key role in serum triglyceride (TG)
metabolism in humans [Kathiresan et al., 2008; Koster et al.,
2005; Romeo et al., 2009; Shimizugawa et al., 2002]. We
conducted a gene-based association analysis by using both
GGRF and SKAT with consideration of potential confound-
ing effects from race and gender. A linear-kernel was used for
SKAT (default option in SKAT), while a D2S metric was used
for GGRF. We started the analysis with the original scale of
serum TG and tested the association of each gene with the
quantitative values of serum TG. To illustrate the application
to the binary phenotype, serum TG was dichotomized at the
highest quartile of each of the six sex-ethnicity groups. We
tested each gene by using two different strategies. First, all
available variants in a gene were tested for their joint asso-
ciation with the phenotype. Second, only nonsynonymous
(NS) variants were tested. The MAF distribution of variants
in each gene was given in Figure 6. For the sake of illustration,
we plotted the genetic variants with MAFs greater than 0.05
as 0.05.
The results were summarized in Table 1, where the as-
sociation findings reaching the nominal significance level
of 0.05 were highlighted. The most significant association
finding came from ANGPTL4, where both methods identi-
fied an association between the nonsynonymous variants of
ANGPTL4 and the TG phenotype. The association results
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Figure 5. Type I error and power of GGRF/SKAT with various similarity-metrics/kernel-metrics. Top left: type I error for quantitative phenotypes;
Bottom left: power for quantitative phenotypes. Top right: type I error for binary phenotypes; Bottom right: power for binary phenotypes. ADJ:
bootstrap adjustment for SKAT, only available with binary phenotypes, linear kernel, and BETA weight.
Figure 6. Distribution of minor allele frequencies in ANGPTL3, ANGPTL4, ANGPTL5, and ANGPTL6 genes in 2,658 subjects from the DHS
sequencing data.
from GGRF attained a higher significance level than those
of SKAT, for both quantitative and binary phenotypes. For
instance, for the binary phenotype, GGRF obtained a P-value
of 0.001,while SKAThad aP-value of 0.015.When all variants
(i.e., both synonymous and nonsynonymous variants) were
considered, the association could only be found by SKAT,
which was also associated with a less significant P-value (i.e.,
P-value = 0.02). A possible explanation is that the association
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Table 1. Application of GGRF and SKAT to the DHS sequencing
data
Quantitative TG Binary TG
# of
variants MAF range GGRF SKAT GGRF SKAT
ANGPTL3 – Fulla 72 0.019–35.8% 0.214 0.120 0.622 0.061
ANGPTL3 – NSb 28 0.019–2.46% 0.037 0.103 0.030 0.016
ANGPTL4 – Full 83 0.019–27.5% 0.801 0.131 0.586 0.020
ANGPTL4 – NS 27 0.019–27.5% 0.008 0.019 0.001 0.015
ANGPTL5 – Full 70 0.019–31.5% 0.308 0.981 0.050 0.761
ANGPTL5 – NS 18 0.019–3% 0.193 0.905 0.101 0.561
ANGPTL6 – Full 59 0.019–5.6% 0.382 0.513 0.297 0.527
ANGPTL6 – NS 27 0.019–1.04% 0.827 0.156 0.726 0.116
a All genetic variants in gene ANGPTL3.
b Nonsynonymous variants in gene ANGPTL3.
was mainly driven by nonsynonymous variants, while the
majority of the synonymous variants were not disease
related.
Neither method found evidence of association for
ANGPTL3 with TG when considering both synonymous
and nonsynonymous variants together. By testing only the
nonsynonymous variants of ANGPTL3, however, GGRF was
able to detect a significant association for both the quanti-
tative TG phenotype (P-value = 0.037) and the binary phe-
notype (P-value = 0.03). As compared to GGRF, SKAT did
not find the association of nonsynonymous variants with the
quantitative TG phenotype, but did identify an association
for the binary TG phenotype (P-value = 0.016). Similar to
ANGPTL4, the association was mainly seen in the nonsyn-
onymous variants of ANGPTL3. Nevertheless, the associa-
tion of the nonsynonymous variants with ANGPTL3 was not
as strong as that with ANGPTL4. GGRF also identified a
marginal association for ANGPL5 with the binary TG phe-
notype when considering both synonymous and nonsynony-
mous variants together (P-value = 0.05); while SKAT did not
find any association between ANGPL5 and either quantita-
tive or binary TG phenotype. No association was identified
for ANGPTL6 using either method. This might indicate that
ANGPL6 makes no contribution to the variation of TG. It
could also be possible that the majority of the variants in
ANGPTL6 were noncausal, so that neither method had suf-
ficient power to detect any association.
Discussion
A random field is a stochastic process that takes values in
a Euclidean space with specific geometric structure [Adler
and Taylor, 2007]. It has been extensively studied in theory
and has been widely used in areas such as spatial analysis and
imaging analysis. However, despite its natural advantage for
high-dimensional data analyses, it has rarely been adopted in
genetic research. In this article, we have proposed a GGRF
method for association analysis of sequencing data underly-
ing various types of phenotypes (e.g., binary and continu-
ous phenotypes). GGRF is built on a Euclidean space with
a flexible dimensionality determined by the number of se-
quence variants.With such a geometric structure, the genetic
similarities between subjects can be naturally measured by
their p-norm distance, and then connected to their pheno-
typic similarities. As a similarity-basedmethod, it follows the
same assumptions of SKAT and SIMreg in that, if there is a
gene–phenotype association, the genetic similarity between
subjects contributes to their phenotypic similarity. The pro-
posed GGRF has several appealing features over burden tests,
such as avoiding the selection of thresholds for rare vari-
ants, allowing for multiple variants with different directions
andmagnitude of effects, and being computationally efficient
without requiring a permutation test. Empirically, we have
demonstrated that GGRF attained higher power than SKAT
when rare variants had relatively larger effect sizes than com-
mon variants, or when the majority of variants were causal.
Previous studies have shown that if the phenotype was binary
and the sample size was small (e.g., less than 2,000), SKAT
could yield conservative results, leading to incorrect type I
error and power loss [Lee et al., 2012; Lin and Tang, 2011;
Wu et al., 2011]. Our simulation results were consistent with
this previous finding. In addition, we also found a conser-
vative type I error of SKAT for quantitative phenotypes with
a relatively small sample size (n = 697) and extremely rare
variants (e.g., MAF = 0.07%). On the other hand, because
of its asymptotic property, GGRF has well-controlled type I
error, even for a small sample size. This feature makes GGRF
more suitable for sequencing studieswith a small tomoderate
sample size (i.e., n < 2,000).
GGRF has also a close connection to SKAT. SKAT is a ker-
nel machine-based method, which models genetic effects as
a variance component in a linear mixed model. It uses a ker-
nel function to summarize the similarity between pairs of
individuals. Similarly, GGRFmodels the covariates paramet-
rically and genetic effects in a nonparametric fashion. When
phenotypes follow a normal distribution, we can show that
there is a close connection between GGRF and SKAT. We de-
note the kernel matrix in SKAT asK and the similarity matrix
in GGRF as S, whereK and S are the same except the diagonal
elements of S are zeros. The SKAT model can be written as a
linear-mixed model,
Y ∼ Xβ + υ, υ ∼ N(0, σ2I + τ2K ).
I is an N × N identity matrix and σ2 is the variance of
Yi under the null hypothesis; τ2K represents the variance
component for the genetic effects [Kwee et al., 2008; Liu et al.,
2007; Wu et al., 2010]. By using the factorization theorem of
Besag [Besag, 1974], the GGRF model can be expressed as,
Y ∼ Xβ + ν, ν ∼ N(0, σ2(I – γS)–1).
The coefficient γ measures the magnitude of genetic effects.
Under the null hypothesis of no association (i.e., τ = 0 in
SKAT or γ = 0 in GGRF), the two models are equivalent.
Although both SKAT and GGRF evaluate the association by
testing a coefficient in the covariance matrix, the two meth-
ods model genetic effects differently, resulting in different
performance. In addition, SKAT adopts a score test while
GGRF uses aWald type of statistic, which also leads to differ-
ent power in testing the genetic association. Another differ-
ence between SKAT and GGRF is different similarity metrics
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they used. Because of the geometric structure of GGRF, the
similarity metric is defined based on the p-norm distance be-
tween genetic vectors, and thus some kernel functions (e.g.,
the linear kernel) of SKAT cannot be used as similarity met-
rics forGGRF. In fact, the linear kernel of SKAT can be viewed
as the inner product of two genetic vectors. In aHilbert Space
(e.g., a genetic space), the corresponding distance metric of
the linear kernel would be the commonly used Euclidean dis-
tance (i.e., 2-norm distance) as in GGRF. GGRF is not able
to use a linear kernel directly, but the corresponding D2S
metric, which has a same computational speed as the linear
kernel, can be used.
In the analysis of sequencing data, a wide variety of weight
functions have been proposed to adjust for the contributions
of rare variants to diseases. It is worthwhile to study how dif-
ferent weights influence association tests. In this study, our
simulation results have demonstrated that the performance
of a weight function is inherently determined by the under-
lying disease model. The ideal choice of weights for sequence
variants should be proportional to their effects on the phe-
notype. For example, ideally, a noise variant should be given
a weight of zero. Previous study also indicated that weights
based on estimated effects of variants help tominimize power
loss due to the inclusion of noncausal variation [Liu et al.,
2013]. However, the estimation of adaptive weights from the
same study utilizes phenotype information, and thus the per-
mutation test is required to account for inflated type I error.
The asymptotic test is only valid when empirical weights are
estimated from other independent studies. In practice, the
weight function should be carefully selected based on the
purpose of the study and available prior knowledge. For ex-
ample, if the aim of a study is to test the joint association of
both common and rare variants, the BETA and LOG weights
appear to be better choices than the WSS weight, while the
WSS weight might be more suitable to detect rare variants
with large effects.
In this article, we studied two types of phenotypes, quanti-
tativephenotypes andbinaryphenotypes, using aGEE frame-
work. Based on GEE, our method can also be easily applied
to phenotypes with various distributions (e.g., a Poisson dis-
tribution) by simply changing the link function in equation
(2). Another advantage of using GEE is that it allows us in
the future to further extend the GGRF to handle multiple
phenotypes or repeated measurements.
In the empirical study of the DHS, both methods found
evidence of association between nonsynonymous variants in
the genesANGPTL3,ANGPTL4, andTG. In this study, GGRF
showed someadvantage over SKAT for detecting themost sig-
nificant association, i.e., the association between ANGPTL4
and TG. Nevertheless, the performance of the twomethods is
essentially influenced by the underlying diseasemodel. So far,
we still have limited knowledge of ANGPTL3 and ANGPTL4
in regard to their role in TG and the contribution of rare vari-
ants in ANGPTL3 and ANGPTL4 to TG. Further studies will
be needed to validate this preliminary finding and further
evaluate the role of rare variants in TG.
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Appendix A
The Influence of Different Similarity Metrics on
the Performance of GGRF
In GGRF, individuals are mapped into a genetic space
spanned by their sequenced genotypes. The conditional phe-
notype mean of each individual can then be modeled as a
linear function of a weighted sum of phenotypes of the re-
maining individuals, where the weights are determined by
the genetic similarity between individuals. If there is an as-
sociation between sequenced genotypes and phenotypes, we
expect individuals who are adjacent to a particular individual
(i.e., those are genetically similar to the individual) provide
more weights than individuals who are further apart (i.e.,
those are genetically different to the individual). Because of
the unique feature of GGRF, the performance of GGRF relies
on the measurement of genetic similarity and how it reflects
the underlying genetic similarity. Below we briefly discuss
the choice of similarity metrics and how they influence the
performance of GGRF.
In a sequencing study where each causal variant is only
carried by a small number of individuals, individuals tend
to distribute sparsely in the genetic space. If an individual
has a limited number of nearby individuals, the model will
then uses the remote individuals to approximate the indi-
vidual. By using the general p-norm distance-based genetic
similarity (NDS) proposed in the equation (1), remote in-
dividuals who carry causal variants on the other loci of the
region are assigned positive weights and are contributed to
the model. When rare variants in the region have the same
direction of effects, an individual can bemodeled not only by
individuals carrying the same rare variants but also individ-
uals carrying other causal variants. This is especially helpful
for testing variants with very low frequency (e.g., singleton
rare variants), where individuals carrying other rare variants
and having similar phenotypes are used for improved perfor-
mance. In addition, power of GGRF based on NDS increases
when numbers of causal variants in the region increases. As
we observed in the simulation II (Fig. 4), GGRF gained sub-
stantial power increase over SKAT when the proportion of
causal variants is high.
Although NDS proposed in the equation (1) have the ad-
vantages for detecting rare variants with the same direction
of effects, it is less powerful for detecting rare variants with
bidirectional effects. In the later scenario, each individual is
approximated by individuals carrying other causal variants
and having potentially different phenotypes. This is much
less an issue with the increase of MAF. With the increase of
MAF, an individual carrying the causal variant is surrounded
by enough number of individuals carrying the same vari-
ants and remote individuals carrying other variants play less
important role in the model. Through a preliminary simu-
lation (data is not shown), GGRF is robust to bidirectional
effects when MAF reaches 0.05. To detect rare variants with
bidirectional effects, we propose a centered NDS,
Scen = (I – J )S(I – J ),
where S is an N × N similarity matrix with si,j as defined
in equation (1), I is N × N identity matrix, and J is N × N
matrix with all elements being 1/N; the diagonal elements
of Scen were further set to 0. With the centered NDS, distant
individuals with different phenotypes are assigned negative
weights. As demonstrated by our simulations, GGRF using
the centered NDS was robust to rare variants with bidirec-
tional effect. Moreover, we observed that GGRF using the
centered NDS was robust to noncausal variants, but did not
have same advantage as NDS when majority of rare variants
were causal (Fig. B1). Note that the centered NDS is also
useful for identifying variants with very low frequency by
incorporating the information from individuals with neg-
ative weights, i.e., the individuals not carrying the vari-
ant also contribute to the approximation but with negative
weights.
We conclude that GGRFwithNDS attains improved power
when the effects of rare variants in a genetic region have the
same direction, but is less robust to noncausal variants and
bidirectional effects. GGRF with the centered NDS is ro-
bust to noncausal variants and bidirectional effects but is
less powerful for detecting rare variants with same direc-
tion of effects. Ideally, we can optimally combine these two
similarity metrics for maximum performance under both
scenarios. We will further study this optimal GGRF and
compare its performance with that of SKAT-O in our future
work.
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Appendix B
Comparison of GGRF, SKAT, and Burden Test for
Both One-direction and Bidirection of Effect Sizes
Simulation Setting
To evaluate the power of three methods, we randomly se-
lected 30 variants as causal variants and gradually increased
the number of noise variants to ensure the total number of
variants were 100, 150, 300, and 508. Therefore, the propor-
tions of causal variants were approximately 30%, 20%, 10%,
and 6%. Simulation studies were conducted for both one-
direction and bidirection of effect sizes. For one-direction
of effect size, all 30 causal variants had positive effects. For
bidirection of effect sizes, 15 of 30 causal variants were ran-
domly selected with negative effects. The phenotypes were
simulated under disease model S4, and BETA weights were
used for all three methods. An IBS kernel was used for SKAT,
while a centered-IBS was used for GGRF.
To evaluate the type I error of three methods, the phe-
notypes were simulated indecently from the genotypes, and
the number of variants increased from 100, 150, 300, and
508.
Simulation Results
The simulation results for both quantitative and binary
phenotypes were summarized in Figure B1. The results
showed the type I errors of GGRF and Burden test were well
controlled at the 5% level. On the other hand, SKAT showed
conservative type I errors, especially for binary phenotypes.
In terms of statistical power, all three methods showed de-
creasing power as the number of noise variants increased. For
one-direction of effect sizes, Burden test attained the high-
est power among three methods, especially when the pro-
portional of causal variants was high (e.g., 30%). Moreover,
SKAT showed higher power than GGRF for both quantitative
and binary phenotypes. For bidirection of effect sizes, Burden
test suffered from a significant power loss, while both GGRF
and SKAT showed comparable power to their one-direction
counterparts, especially when the number of noise variants
was small (e.g., 100 total variants). These results indicated
both GGRF and SKAT were robust to bidirection of effect
sizes. Further, SKAT showed higher power than GGRF for
quantitative phenotypes, while GGRF showed higher power
than SKAT for binary phenotypes.
Figure B1. Type I error and Power of GGRF, SKAT, and Burden test with decreasing ratio of casual variants/noise variants. Left: Quantitative
Phenotypes, Right: Binary Phenotypes; T1E: Type I Error; 1 Direction: one-direction of effect sizes; Bidirection: bidirection of effect sizes.
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